WALTER V. KLEMP Company web. site http://www.moleculin.com
President, CEO and Chairman
Authorized Shares 75,000,000 as of 03/01.2018
Moleculin Announces Engagement with Voisin Consulting Life Sciences to Expand Annamycin Clinical Trial https://globenewswire.com/news-release/2018/05/03/1495957/0/en/Moleculin-Announces-Engagement-with-Voisin-Consulting-Life-Sciences-to-Expand-Annamycin-Clinical-Trial.html Outstanding Shares 24,768,861 as of 03/01/2018 Moleculin Announces New Data Discovery Confirming Significant Increase in Potential to Starve Cancerous Tumors https://ih.advfn.com/p.php?pid=nmona&article=78433601&symbol=MBRX Moleculin receives approval for leukemia clinical trial; shares ahead 23% premarket
https://seekingalpha.com/news/3365150-moleculin-receives-approval-leukemia-clinical-trial-shares-ahead-23-percent-premarket Moleculin Targets accelerated FDA approval of WP1732; Pursues Development for Ocular Tumors
Moleculin Enters Agreement with Seidman Cancer Center to Conduct Leukemia Clinical Trials Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New Discovery http://www.marketwired.com/press-release/moleculin-announces-grant-funded-collaboration-expand-understanding-new-discovery-2246407.htm
Moleculin Biotech, Inc. (Nasdaq: MBRX) to Ring The Nasdaq Stock Market Closing Bell in celebration of IPO
Metabasis Therapeutics (NASDAQ:MBRX)
Historical Stock Chart
Moleculin Biotech (Nasdaq:MBRX), a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, will visit the Nasdaq MarketSite in Times Square to celebrate its initial public offering (IPO).
In honor of the occasion, Walter Klemp, Chief Executive Officer, will ring the Closing Bell.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Thursday, June 2, 2016 – 3:45 p.m. to 4:00 p.m. ET
Moleculin Biotech Media Contact: